Hallucinations And Delusions In Parkinson's Disease Therapeutics
1. Nuplazid patent expiration
Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis; Treatment of parkinson's disease psychosis; Treatment of a neurodegenerative disease or a symptom thereof; Trea...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6756393 | ACADIA PHARMS INC | Azacyclic compounds |
Mar, 2021
(4 years ago) | |
| US7115634 | ACADIA PHARMS INC | 4-aminopiperidine and their use as a medicine |
Oct, 2021
(4 years ago) | |
| US9296694 | ACADIA PHARMS INC | Azacyclic compounds |
Mar, 2021
(4 years ago) | |
| US6815458 | ACADIA PHARMS INC | Azacyclic compounds |
Mar, 2021
(4 years ago) | |
| US7858789 | ACADIA PHARMS INC | Derivatives of 4-aminopiperidine and their use as a medicament |
Dec, 2020
(5 years ago) | |
| US8110574 | ACADIA PHARMS INC | Derivatives of 4-aminopiperidine and their use as a medicament |
Dec, 2020
(5 years ago) | |
| US7732615 | ACADIA PHARMS INC | N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
Jun, 2028
(2 years from now) | |
| US7923564 | ACADIA PHARMS INC | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms |
Sep, 2025
(3 months ago) | |
| US7601740 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Apr, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9765053 | ACADIA PHARMS INC | Methods of treatment using selective 5-HT2A inverse agonists |
Jul, 2022
(3 years ago) | |
| US10028944 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(1 year, 11 months ago) | |
| US10517860 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(11 years from now) | |
| US7659285 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Aug, 2026
(7 months from now) | |
| US10953000 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(11 years from now) | |
| US8921393 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(1 year, 11 months ago) | |
| US8618130 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(1 year, 11 months ago) | |
| US9566271 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(1 year, 11 months ago) | |
| US10849891 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(12 years from now) | |
| US11452721 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(12 years from now) | |
| US10646480 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(12 years from now) | |
| US10449185 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 29, 2021 |
Drugs and Companies using PIMAVANSERIN TARTRATE ingredient
NCE-1 date: 29 April, 2020
Market Authorisation Date: 28 June, 2018
Dosage: CAPSULE; TABLET
How can I launch a generic of NUPLAZID before it's drug patent expiration?
More Information on Dosage
NUPLAZID family patents
